Amplifying natural antitumor immunity for personalized immunotherapy
T-cells engineered with T-cell receptors(TCR-T),chimeric antigen receptor(CAR)T-cells,and neoantigen vaccines have each demonstrated therapeutic success in clinical trials,but many of these therapies can only benefit a small group of patient types owing to the restriction of certain tumor-associated antigens;personalized immunotherapy customizes cancer treatments to each patient,achieving greater responses without damaging normal tissues.In a recent Cell Research paper,He et al.show that TCR-T cells engineered with TCRs from naturally occurring tumor antigen-specific(Tas)T-cells are an effective therapy against non-small cell lung carcinoma,and a promising agent for future immunotherapies.
immunotherapy、natural、amplifying、antitumor、immunity、personalized
32
R730.1;B82-061;H315
2022-08-11(万方平台首次上网日期,不代表论文的发表时间)
共2页
505-506